FDA's U-Turn On Fanapt: Comparative Assessments Must Have Clinical Meaning
The review of Vanda’s Fanapt casts into relief the contours of FDA’s authority to consider comparative efficacy as a factor in drug approval decisions.
The review of Vanda’s Fanapt casts into relief the contours of FDA’s authority to consider comparative efficacy as a factor in drug approval decisions.